GSK PLC SP. ADR/2 NEW (GS70) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GSK PLC SP. ADR/2 NEW (GS70) has a cash flow conversion efficiency ratio of 0.157x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€2.69 Billion ≈ $3.14 Billion USD) by net assets (€17.18 Billion ≈ $20.08 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GSK PLC SP. ADR/2 NEW (GS70) total market value for the company's overall valuation and market capitalisation.
GSK PLC SP. ADR/2 NEW - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how GSK PLC SP. ADR/2 NEW's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GSK PLC SP. ADR/2 NEW Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GSK PLC SP. ADR/2 NEW ranked by their cash flow conversion efficiency. Explore earnings quality score of GSK PLC SP. ADR/2 NEW to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
McKesson Corporation
NYSE:MCK
|
0.057x |
|
UBS Group AG
SW:UBSG
|
-0.043x |
|
Agnico Eagle Mines Limited
TO:AEM
|
0.073x |
|
Cambricon Technologies Corp Ltd
SHG:688256
|
-0.034x |
|
China Yangtze Power Co Ltd
SHG:600900
|
0.084x |
|
Air Liquide SA
PA:AI
|
0.130x |
|
CVS Health Corp
NYSE:CVS
|
0.045x |
|
GlaxoSmithKline plc
MX:GSKN
|
0.141x |
Annual Cash Flow Conversion Efficiency for GSK PLC SP. ADR/2 NEW (2021–2025)
The table below shows the annual cash flow conversion efficiency of GSK PLC SP. ADR/2 NEW from 2021 to 2025. View GSK PLC SP. ADR/2 NEW stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €15.96 Billion ≈ $18.65 Billion |
€7.74 Billion ≈ $9.05 Billion |
0.485x | -3.13% |
| 2024-12-31 | €13.09 Billion ≈ $15.30 Billion |
€6.55 Billion ≈ $7.66 Billion |
0.501x | -5.32% |
| 2023-12-31 | €12.79 Billion ≈ $14.96 Billion |
€6.77 Billion ≈ $7.91 Billion |
0.529x | -27.86% |
| 2022-12-31 | €10.10 Billion ≈ $11.80 Billion |
€7.40 Billion ≈ $8.65 Billion |
0.733x | +96.80% |
| 2021-12-31 | €21.34 Billion ≈ $24.95 Billion |
€7.95 Billion ≈ $9.30 Billion |
0.373x | -- |
About GSK PLC SP. ADR/2 NEW
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more